文献速递肝病

丙型肝炎病毒清除与肝性脑病风险降低相关

Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-10-04

该回顾性队列研究纳入1999至2015年在退伍军人医疗系统启动抗病毒治疗的71457例HCV患者,随访至2018年。DAA治疗获得SVR与肝性脑病发生率显著降低相关(AHR 0.41),且MELD<9者已有HE缓解可能性增加(AHR 2.26),但MELD≥9者未见缓解获益。

要点

  • DAA治疗获得SVR可降低肝性脑病发生风险(AHR 0.41)。
  • SVR与肝性脑病住院风险降低相关(AHR 0.59)。
  • MELD<9者SVR后已有HE缓解率更高(AHR 2.26)。

核心结论

  • DAA清除HCV与肝性脑病发生风险降低59%相关,且除MELD≥9者外,已有HE缓解可能性增加2倍以上。

主要发现

  • DAA治疗获得SVR者肝性脑病发生率为0.28/100人年,无SVR者为1.39/100人年(AHR 0.41;95%CI 0.32-0.51)。
  • 在合并酒精使用障碍、糖尿病、肝硬化(AHR 0.36;95%CI 0.31-0.43)及MELD≥9(AHR 0.36;95%CI 0.30-0.44)患者中关联持续存在。
  • SVR与肝性脑病住院风险降低相关(AHR 0.59;95%CI 0.43-0.81)。
  • 2396例抗病毒治疗时正接受HE药物治疗的患者中,MELD<9者SVR与HE缓解可能性增加相关(AHR 2.26;95%CI 1.74-2.93),MELD≥9者无此关联。

临床怎么用

  • 对HCV感染患者,尤其合并肝硬化或MELD≥9者,应积极给予DAA治疗以实现SVR以降低HE发生风险。
  • MELD<9且正在接受HE药物治疗的患者,获得SVR后HE缓解可能性较高,可考虑密切评估停药可能。

局限性

  • 回顾性研究设计,可能存在残余混杂。
  • 研究人群为退伍军人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is unclear whether a sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy reduces the risk of incident hepatic encephalopathy (HE) in patients with hepatitis C virus (HCV) infection or whether it leads to resolution of pre-existent HE. METHODS: We identified 71,457 patients who initiated antiviral treatments in the Veterans Affairs Healthcare System from January 1, 1999 through December 31, 2015; 35,871 patients (58%) received only interferon, 4535 patients (7.2%) received DAAs plus interferon, and 21,948 patients (35%) received DAA-only regimens. We collected data from patients through October 31, 2018, for an average of 6.6 years. We evaluated the association between SVR and the development of incident HE or the resolution of pre-existent HE (defined by cessation of pharmacotherapy) as well as the risk of hospitalization with HE after adjusting for potential confounders. RESULTS: Compared to no SVR, SVR after DAA therapy was associated with a significantly lower risk of developing HE (0.28 vs 1.39 per 100 person-years; adjusted hazard ratio [AHR] 0.41; 95% CI, 0.32-0.51). This association persisted among patients with co-morbid alcohol use disorder and diabetes as well as patients with cirrhosis (AHR, 0.36; 95% CI, 0.31-0.43) and model for end-stage liver disease (MELD) scores of 9 or more (AHR, 0.36; 95% CI, 0.30-0.44). SVR was also associated with reduced risk of hospitalization with HE (AHR, 0.59; 95% CI, 0.43-0.81). Among 2396 patients who were receiving pharmacotherapy for HE at the time of antiviral treatment, SVR was associated with a significantly increased likelihood of HE resolution for those with MELD scores below 9 (AHR, 2.26; 95% CI, 1.74-2.93) but not those with MELD scores of 9 or more. CONCLUSIONS: In a retrospective study of veterans, we found DAA eradication of HCV infection to be associated with a 59% reduction in risk of development of HE and a > 2-fold increased likelihood of resolution of pre-existing HE in all subgroups except patients with MELD scores of 9 or more.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Parikh ND, Green PK, et al. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. Clin Gastroenterol Hepatol. 2019. PMID: 31589975. doi:10.1016/j.cgh.2019.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。